2024-12-12 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a diversified healthcare company, has significantly underperformed the S&P 500 (VOO) over the period analyzed.  The cumulative return for JNJ is 27.57%, while the S&P 500's cumulative return is 120.40%. This represents a substantial difference of -92.8 percentage points.  The relative divergence of -92.8 places JNJ near the lower bound of its historical range against the S&P 500.  The provided CAGR data shows varying performance across different periods, with some years showing positive outperformance and others showing significant underperformance compared to the S&P 500.  The consistently low or negative alpha suggests that JNJ has not significantly outperformed the market, adjusted for its beta (market risk).


**2. Recent Price Movement:**

* **Closing Price:** $149.23 (Last Market: $146.86)
* **5-day Moving Average:** $149.63
* **20-day Moving Average:** $152.35
* **60-day Moving Average:** $157.59

The price is currently below all three moving averages, suggesting a potential downward trend. The recent closing price ($149.23) is higher than the last market price reported ($146.86), which shows a minor upward movement.


**3. Technical Indicators and Expected Return:**

* **RSI:** 38.47 (below 50, suggesting oversold conditions)
* **PPO:** -0.18 (negative, indicating bearish momentum)
* **Recent Relative Divergence:** +1.5 (short-term upward trend)
* **Expected Return:** 0.0% (The provided information does not quantify a more precise expected return beyond the stated 0.0% relative to the S&P 500 over a long-term horizon.)

The RSI and PPO indicators suggest bearish momentum, despite the recent small upward price movement. The discrepancy between the technical indicators and the recent relative divergence might be due to short-term fluctuations.  A more detailed technical analysis would be needed to provide a better interpretation. Note that the last market price is a considerable drop, and this could be influencing the current outlook. There is no mention in the data of a sharp price fluctuation.



**4. Recent Earnings Analysis:**

The reported earnings show some volatility in EPS and relatively stable revenue.

* **Revenue:** Revenue remained relatively flat around $22B in the last two quarters and slightly lower in previous quarters.  There is not a clear discernible trend.
* **EPS:** EPS fluctuated significantly across quarters, with the highest value of $10.32 in Q4 2023 (an outlier) and lower values in subsequent quarters.  This high EPS in Q4 2023 needs further investigation to understand the factors contributing to this unusually high figure in comparison to other quarters.  Without additional context, it's challenging to determine if these fluctuations are indicative of a trend or simply short-term variation.

**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue has remained relatively stable, fluctuating around $21-22B. Profit margins are consistently high (68-69%), suggesting strong profitability.
* **Capital and Profitability:** Equity fluctuates.  The Return on Equity (ROE) is highly variable, ranging from 3.84% to 36.54%.  The exceptionally high ROE of 36.54% in Q3 2023 warrants further investigation to understand the underlying reasons behind this outlier data point.

The financial data show mixed signals. While profitability remains strong, the variability in ROE raises concerns that need further exploration beyond the data provided.


**6. News and Recent Issues:**

No specific news or recent issues are provided in the data.  Further research would be needed to ascertain any recent market outlooks, analyst opinions, or performance highlights regarding JNJ.  This section requires external data to complete.

**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the given period. While its profitability remains strong, several data points require further investigation: the unexpectedly high EPS in Q4 2023 and the highly variable ROE.  Technical indicators suggest bearish momentum, although the recent price action shows a slight upward tick.   A deeper dive into the reasons for the fluctuations in EPS and ROE, along with additional news and analyst sentiment, is crucial for a comprehensive evaluation.  The 0% long-term expected return relative to the S&P 500 suggests that JNJ does not offer superior performance over the long haul.  Without additional information, such as an explanation for the abnormally high Q4 2023 EPS and ROE figures, it's difficult to provide a definitive assessment of JNJ's future prospects.  Further research is strongly recommended.


**8. Disclaimer:** This analysis is based solely on the provided data and does not constitute financial advice.  Investing involves risk, and past performance is not indicative of future results.  Always conduct thorough due diligence and consult with a qualified financial advisor before making any investment decisions.
